» Articles » PMID: 23361464

Differential Roles for MBD2 and MBD3 at Methylated CpG Islands, Active Promoters and Binding to Exon Sequences

Overview
Specialty Biochemistry
Date 2013 Jan 31
PMID 23361464
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

The heterogeneous collection of nucleosome remodelling and deacetylation (NuRD) complexes can be grouped into the MBD2- or MBD3-containing complexes MBD2-NuRD and MBD3-NuRD. MBD2 is known to bind to methylated CpG sequences in vitro in contrast to MBD3. Although functional differences have been described, a direct comparison of MBD2 and MBD3 in respect to genome-wide binding and function has been lacking. Here, we show that MBD2-NuRD, in contrast to MBD3-NuRD, converts open chromatin with euchromatic histone modifications into tightly compacted chromatin with repressive histone marks. Genome-wide, a strong enrichment for MBD2 at methylated CpG sequences is found, whereas CpGs bound by MBD3 are devoid of methylation. MBD2-bound genes are generally lower expressed as compared with MBD3-bound genes. When depleting cells for MBD2, the MBD2-bound genes increase their activity, whereas MBD2 plus MBD3-bound genes reduce their activity. Most strikingly, MBD3 is enriched at active promoters, whereas MBD2 is bound at methylated promoters and enriched at exon sequences of active genes.

Citing Articles

Role of the NuRD complex and altered proteostasis in cancer cell quiescence.

Jiang Q, Jiang Q, Ertel M, Arrigo A, Sannino S, Goeckeler-Fried J bioRxiv. 2025; .

PMID: 39990343 PMC: 11844430. DOI: 10.1101/2025.02.10.637435.


MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5.

Wang D, Chen J, Wu G, Xiong F, Liu W, Wang Q J Exp Clin Cancer Res. 2024; 43(1):272.

PMID: 39350229 PMC: 11440836. DOI: 10.1186/s13046-024-03188-4.


Reader-Effectors as Actuators of Epigenome Editing.

Kim S, Haynes K Methods Mol Biol. 2024; 2842:103-127.

PMID: 39012592 DOI: 10.1007/978-1-0716-4051-7_5.


Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells.

Sahu R, Tandon S, Singh S, Das B, Hedau S BMC Cancer. 2024; 24(1):566.

PMID: 38711004 PMC: 11071212. DOI: 10.1186/s12885-024-12274-x.


CARM1 hypermethylates the NuRD chromatin remodeling complex to promote cell cycle gene expression and breast cancer development.

Chen X, Huang M, Fan D, He Y, Zhang W, Ding J Nucleic Acids Res. 2024; 52(12):6811-6829.

PMID: 38676947 PMC: 11229315. DOI: 10.1093/nar/gkae329.


References
1.
Kolodziej K, Pourfarzad F, de Boer E, Krpic S, Grosveld F, Strouboulis J . Optimal use of tandem biotin and V5 tags in ChIP assays. BMC Mol Biol. 2009; 10:6. PMC: 2644297. DOI: 10.1186/1471-2199-10-6. View

2.
Morey L, Brenner C, Fazi F, Villa R, Gutierrez A, Buschbeck M . MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol. 2008; 28(19):5912-23. PMC: 2546998. DOI: 10.1128/MCB.00467-08. View

3.
Hu G, Wade P . NuRD and pluripotency: a complex balancing act. Cell Stem Cell. 2012; 10(5):497-503. PMC: 3348611. DOI: 10.1016/j.stem.2012.04.011. View

4.
Zhang Y, Liu T, Meyer C, Eeckhoute J, Johnson D, Bernstein B . Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008; 9(9):R137. PMC: 2592715. DOI: 10.1186/gb-2008-9-9-r137. View

5.
BOEKE J, Ammerpohl O, Kegel S, Moehren U, Renkawitz R . The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A. J Biol Chem. 2000; 275(45):34963-7. DOI: 10.1074/jbc.M005929200. View